LOS ALTOS, Calif., Sept. 15, 2021 /PRNewswire/ — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the Company is scheduled to be added as a member…

Click here to view the original article.